Induced Pluripotent Stem Cells: Global Markets
BCC Research（BCCリサーチ）「iPS細胞(人工多能性幹細胞)の世界市場 – Induced Pluripotent Stem Cells: Global Markets」は世界のiPS細胞市場を調査し、主要セグメント毎に分析・予測を行っています。
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 and forecast to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 through 2028.
This study focuses on the market side of iPSCs rather than the technical side. Different market segments for this emerging market are covered. For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis. Application-based market segments include drug development and toxicity testing, academic research, and regenerative medicine. iPSC-derived cell type-based market segments include hepatocytes, neurons, cardiomyocytes, endothelial cells, and other cell types. Other cell types are comprised of astrocytes, fibroblasts, and hematopoietic and progenitor cells, among other substances. Geographical-based market segments include the U.S., Asia-Pacific, Europe, and the Rest of the World. The research and market trends are also analyzed by studying the funding, patent publications, and research publications in the field.
This report focuses on the market size and segmentation of iPSC products, including iPSC research and clinical products. The market for iPSC-related contract services is also discussed. iPSC research products are defined as all research tools, including iPSCs and various differentiated cells derived from iPSCs, various related assays and kits, culture media and medium components (e.g., serum, growth factors, inhibitors), antibodies, enzymes, and products that can be applied for the specific purpose of executing iPSC research. For this report, iPSC products do not cover stem cell research and clinical products that are broadly applicable to any stem cell type.
This report discusses key manufacturers, technologies, and factors influencing market demand, including the driving forces and limiting factors of the iPSC market’s growth. Based on these facts and analysis, the market trends and sales for research and clinical applications are forecast through 2028. One particular focus on the application of iPSCs was given to drug discovery and development, which includes pharmaco-toxicity screening, lead generation, target identification, and other preclinical studies; body-on-a-chip; and 3D disease modeling. Suppliers and manufacturers of iPSC-related products are discussed and analyzed based on their market shares, product types, and geography. An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSC market.
Detailed technologies such as those for generating iPSCs, differentiating iPSCs and controlling the differentiation, and large-scale manufacturing of iPSCs and their derivative cells under Good Manufacturing Practice (GMP) compliance or xeno-free conditions are excluded from the study. They are beyond the scope of this report.
The induced pluripotent stem cell market has been analyzed for four main geographic regions: The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW). The report will provide details with respect to induced pluripotent stem cells.
|Base year considered
|Forecast period considered
|Base year market size
|Market size forecast
|CAGR of 9.1% from 2023 to 2028
|By Reprogramming Method, Application, Method, Derived Tissue Cell Type, Species, Product Function, End Use, and Geographic Region
|The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW)
|Key Market Drivers
|Growing Research and Development in iPSCs
Increased Investment in Biotechnology Industry
Rising Prevalence of Chronic Diseases
ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS INC.
APPLIED BIOLOGICAL MATERIALS INC. (ABM)
APPLIED STEMCELL INC.
AXOL BIOSCIENCE LTD.
BRISTOL MYERS SQUIBB (IPIERIAN)
CELL SIGNALING TECHNOLOGY (CST)
FUJIFILM CELLULAR DYNAMICS INC. (FCDI)
ID PHARMA CO. LTD.
LONZA GROUP LTD.
SCIENCELL RESEARCH LABORATORIES
SYSTEM BIOSCIENCES INC.
TAKARA BIO USA INC. (CLONTECH LABORATORIES)
THERMO FISHER SCIENTIFIC
VERTEX PHARMACEUTICALS INC.